Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 39.65% is 545% above its 5-year average of -8.90%, near the high end of its 5-year range (-33.30%–39.65%).
102.04% above its 12-month average of 19.63%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 4.72%.
RETURN ON ASSETS (ROA)
39.65%
RETURN ON ASSETS (ROA) AVG TTM
19.63%
RETURN ON ASSETS (ROA) AVG 3Y
0.51%
RETURN ON ASSETS (ROA) AVG 5Y
-8.90%
RETURN ON ASSETS (ROA) AVG 10Y
-23.47%
RETURN ON ASSETS (ROA) AVG 15Y
-27.97%
RETURN ON ASSETS (ROA) AVG 20Y
-38.85%
CURRENT VS TTM AVG
+102.04%
CURRENT VS 3Y AVG
+7674.51%
CURRENT VS 5Y AVG
+545.42%
CURRENT VS 10Y AVG
+268.91%
CURRENT VS 15Y AVG
+241.75%
CURRENT VS 20Y AVG
+202.06%
SECTOR MEDIAN · HEALTHCARE
-29.10%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
+236.25%
vs the sector median at left
Aurinia Pharmaceuticals Inc.
Market Cap
$2.01B
Return on Assets (ROA)
39.65%
TTM Avg
19.63%
3Y Avg
0.51%
5Y Avg
-8.90%
Market Cap
$2.01B
Return on Assets (ROA)
-52.34%
TTM Avg
-54.87%
3Y Avg
-41.09%
5Y Avg
-94.89%
Market Cap
$2.02B
Return on Assets (ROA)
-68.96%
TTM Avg
16.60%
3Y Avg
-13.89%
5Y Avg
-23.58%
Market Cap
$2.00B
Return on Assets (ROA)
14.58%
TTM Avg
11.33%
3Y Avg
2.89%
5Y Avg
-3.84%
Market Cap
$2.04B
Return on Assets (ROA)
-11.31%
TTM Avg
-8.55%
3Y Avg
-34.29%
5Y Avg
-31.66%
Market Cap
$2.05B
Return on Assets (ROA)
-3.14%
TTM Avg
-22.75%
3Y Avg
-10.43%
5Y Avg
-6.58%
Market Cap
$1.97B
Return on Assets (ROA)
-11.00%
TTM Avg
-5.98%
3Y Avg
-9.46%
5Y Avg
-10.43%
Market Cap
$1.96B
Return on Assets (ROA)
-11.05%
TTM Avg
-19.34%
3Y Avg
-25.88%
5Y Avg
-26.23%
Market Cap
$1.94B
Return on Assets (ROA)
-44.98%
TTM Avg
-76.52%
3Y Avg
-94.59%
5Y Avg
-76.85%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.01B | 39.65% | 19.63% | 0.51% | -8.90% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.01B | -52.34% | -54.87% | -41.09% | -94.89% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | -68.96% | 16.60% | -13.89% | -23.58% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.00B | 14.58% | 11.33% | 2.89% | -3.84% |
| Alvotech (ALVO)vs › | $2.04B | -11.31% | -8.55% | -34.29% | -31.66% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.05B | -3.14% | -22.75% | -10.43% | -6.58% |
| AxoGen, Inc. (AXGN)vs › | $1.97B | -11.00% | -5.98% | -9.46% | -10.43% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.96B | -11.05% | -19.34% | -25.88% | -26.23% |
| Immunome, Inc. (IMNM)vs › | $1.94B | -44.98% | -76.52% | -94.59% | -76.85% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 7.23% | 5.94% | 5.72% | 5.23% |
ROA
39.6%
ROE
51.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 38.21% |
| 2024-12-31 | 1.04% |
| 2023-12-31 | -14.24% |
| 2022-12-31 | -22.97% |
| 2021-12-31 | -33.30% |
| 2020-12-31 | -22.15% |
| 2019-12-31 | -27.25% |
| 2018-12-31 | -43.96% |
| 2017-12-31 | -37.29% |
| 2016-12-31 | -40.87% |
| 2015-12-31 | -55.43% |
| 2014-12-31 | -31.78% |
| 2013-12-31 | -11.00% |
| 2012-12-31 | -234.10% |
| 2011-12-31 | -16.81% |
| 2010-12-31 | -35.60% |
| 2009-12-31 | -79.58% |
| 2008-12-31 | -59.58% |
| 2007-12-31 | -79.27% |
| 2006-12-31 | -74.59% |
| 2005-12-31 | -53.50% |
| 2004-12-31 | -36.88% |
| 2003-12-31 | -19.68% |
| 2002-12-31 | -0.72% |
| 2001-12-31 | -19.98% |
| 2000-11-30 | -44.99% |
| 1999-11-30 | -29.51% |
| 1998-11-30 | -141.67% |
